Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Wide K et al. | Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. | 2008 | Br J Clin Pharmacol | pmid:18279471 |
Vanhove T et al. | Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. | 2016 | Br J Clin Pharmacol | pmid:27501475 |
Diczfalusy U et al. | 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. | 2011 | Br J Clin Pharmacol | pmid:21219398 |
Diczfalusy U et al. | 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. | 2009 | Br J Clin Pharmacol | pmid:19006545 |
Higashi T et al. | LC/MS/MS of steroids having vicinal diol as electrospray-active boronates. | 2013 | Chem. Pharm. Bull. | pmid:23449202 |
Goodenough AK et al. | Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. | 2011 | Chem. Res. Toxicol. | pmid:21728364 |
DeGorter MK et al. | Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. | 2013 | Circ Cardiovasc Genet | pmid:23876492 |
Jiang X et al. | An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects. | 2017 | Clin Pharmacol Drug Dev | pmid:27138546 |
Wollmann BM et al. | 4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State. | 2017 | Clin Transl Sci | pmid:27991741 |
Shin KH et al. | Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. | 2013 | Clin. Pharmacol. Ther. | pmid:23784264 |